A Study of De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With B-cell NHL (DI-Leu16-IL2)
A Phase I/II Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered Subcutaneously in Patients With B-cell Non-Hodgkin Lymphoma (NHL)
Sponsor: Alopexx Oncology, LLC
Terminated
Clinical benefit was noted in the earlier portion of the trial; hence, participants were not enrolled in 2 expansion cohorts and the study was terminated early.
Other terminated trials from Alopexx Oncology, LLC
More terminations from Alopexx Oncology, LLC
Listed as NCT01874288, this PHASE1/PHASE2 trial focuses on B-cell Non-Hodgkin Lymphoma and remains terminated or withdrawn. Sponsored by Alopexx Oncology, LLC, it has been updated 9 times since 2013, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE1_PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
Status: Completed → Terminated
▶ Show 4 earlier versions
-
Jun 2018 — Dec 2020 [monthly]
Completed PHASE1_PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
-
Feb 2017 — Feb 2018 [monthly]
Completed PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1_PHASE2
First recorded
Nov 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Alopexx Oncology, LLC
For direct contact, visit the study record on ClinicalTrials.gov .